Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BioCryst ( (BCRX) ) has issued an update.
On July 31, 2025, BioCryst Pharmaceuticals announced the retirement of Jon Stonehouse as President and CEO, effective December 31, 2025, with Charlie Gayer appointed as the new President effective August 1, 2025, and CEO starting January 1, 2026. Gayer, who has been instrumental in the commercial success of ORLADEYO and shaping the company’s business strategy, is expected to continue driving growth and value creation for stakeholders.
The most recent analyst rating on (BCRX) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on BioCryst stock, see the BCRX Stock Forecast page.
Spark’s Take on BCRX Stock
According to Spark, TipRanks’ AI Analyst, BCRX is a Neutral.
BioCryst’s strong earnings call and strategic corporate events are overshadowed by weak financials and technicals. The company must address profitability and leverage to improve its stock appeal.
To see Spark’s full report on BCRX stock, click here.
More about BioCryst
BioCryst Pharmaceuticals is a global biotechnology company focused on improving the lives of individuals with hereditary angioedema and other rare diseases. The company specializes in structure-guided drug design to develop oral small-molecule and protein therapeutics, including the commercialized ORLADEYO® (berotralstat), a first-in-class oral plasma kallikrein inhibitor.
Average Trading Volume: 4,492,204
Technical Sentiment Signal: Hold
Current Market Cap: $1.69B
See more data about BCRX stock on TipRanks’ Stock Analysis page.